Managing Director & Senior Partner
Mark Lubkeman is based in London, and is the current leader of Boston Consulting Group’s Biopharma Transformation business. Until recently, he was the global leader of BCG’s Biopharma business. He is a core member of the Health Care and Marketing, Sales & Pricing practices at BCG.
Since joining the firm in 2001, Mark has focused his client work on the biotech, pharma, and medical device industries, as well as the overall health care sector. He has also worked in BCG's Los Angeles and Zurich offices.
Mark has gained extensive global experience helping clients achieve competitive advantage by developing and implementing winning corporate and commercial strategies, capabilities, and organizations.
Before joining BCG, Mark headed the Los Angeles office of the Monitor Group. He was also a captain in US Army Military Intelligence.
Acquirers need to plan their integrations carefully and act quickly, but too often they delay decision making and destroy value.
Teams often struggle to execute external licensing agreements and M&A transactions that can supplement internal innovation and revenue. Six factors can enhance performance.
A new global survey reveals patient priorities around engagement, innovation and impact, and how pharma companies can benefit by becoming more patient centric.
BCG has taken a look at how biopharma can succeed in the next decade, and we’ve identified five major business imperatives.
Pockets of opportunity await generic-drug companies that are prepared to adopt new strategies.
Agile can help pharma companies deal with an intractable obstacle.
Established models in other industries offer pharma companies promising economic incentives to pursue disease eradication.
Although small in scale relative to the acquiring company, midsize acquisitions are becoming important to creating value in the biopharmaceutical industry.
Here’s how managers can make even a high-performing sales force more productive—and increase the revenue and profits of the business by 10% to 15%.
The health care industry is changing, and biopharmaceutical companies need to take decisive action to ensure that their recent strong value-creation performance remains sustainable.
Pharma companies must adapt to vast changes in health care by forming long-term strategic relationships founded on joint value creation with customers.